Polynovo Ltd
ASX:PNV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (17.4), the stock would be worth AU$0.64 (37% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 27.6 | AU$1.01 |
0%
|
| Industry Average | 17.4 | AU$0.64 |
-37%
|
| Country Average | 14.1 | AU$0.51 |
-49%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Polynovo Ltd
ASX:PNV
|
694.3m AUD | 27.6 | 71.7 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 36.2 | 38.6 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 17.4 | 37.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
94.7B DKK | 16.5 | 23.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD | 20.9 | 33 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 15.2 | 32.7 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 36.2 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
890.2B JPY | 20.8 | 50.3 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
36.7B CNY | 24.7 | 23.3 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | -86.3 | -36.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 9.3 |
| Median | 14.1 |
| 70th Percentile | 24.1 |
| Max | 9 251.5 |
Other Multiples
Polynovo Ltd
Glance View
Polynovo Ltd. engages in the provision biodegradable medical devices. The company is headquartered in Melbourne, Victoria and currently employs 122 full-time employees. The Company’s principal activity is the development of medical devices for various applications. The Company’s products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM is a man-made synthetic polymer that does not contain any biologic materials. BTM is a skin treatment. NovoSorb is a polymer, which is utilizes for the manufacture of novel medical devices, such as Biocompatible polymers. These biocompatible polymers are designed to support different functions of the body and then biodegrade into by-products that can be absorbed and excreted by the body. The company can be produced in a range of formats with different mechanical and degradation properties. In addition to NovoSorb BTM, they can be used for thermoplastic extrusions, filaments for weaving or knitting and as a solution for spray or dip coatings of other devices.
